Corcept Therapeutics Incorporated
DE ˙ DB ˙ US2183521028
63,24 € ↓ -0,74 (-1,16%)
2026-06-05
DEL PRIS
SecurityDE:HTD / Corcept Therapeutics Incorporated
InstitutionCresset Asset Management, LLC
Latest Disclosed Ownership14,544 shares
Latest Disclosed Value $ 586,248
Cresset Asset Management, LLC reports 1.68% decrease in ownership of HTD / Corcept Therapeutics Incorporated

On May 15, 2026 - Cresset Asset Management, LLC filed a 13F-HR form disclosing ownership of 14,544 shares of Corcept Therapeutics Incorporated (DE:HTD) valued at $501,623 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 14,792 shares of Corcept Therapeutics Incorporated. This represents a change in shares of -1.68% during the quarter. The current value of the position is $919,763 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CORCEPT THERAPEUTICS COM 218352102 14,544 -248 -1.68 586 14.01 0.0025
2026-02-17 2025-12-31 13F CORCEPT THERAPEUTICS COM 218352102 14,792 839 6.01 515 -55.65 0.0022
2026-01-22 2025-09-30 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 13,953 -1,064 -7.09 1,160 5.17 0.0051
2025-11-12 2025-09-30 13F CORCEPT THERAPEUTICS COM 218352102 40,877 25,860 3,397 0.0128
2026-01-22 2025-06-30 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 15,017 -77,788 -83.82 1,102 -89.60 0.0055
2025-08-13 2025-06-30 13F CORCEPT THERAPEUTICS COM 218352102 42,640 -50,165 3,130 0.0136
2025-05-13 2025-03-31 13F CORCEPT THERAPEUTICS COM 218352102 92,805 -7,170 -7.17 10,600 110.44 0.0528
2025-02-14 2024-12-31 13F CORCEPT THERAPEUTICS COM 218352102 99,975 18,865 23.26 5,038 34.21 0.0241
2024-11-14 2024-09-30 13F CORCEPT THERAPEUTICS COM 218352102 81,110 2,941 3.76 3,754 47.81 0.0144
2024-08-14 2024-06-30 13F CORCEPT THERAPEUTICS COM 218352102 78,169 8,079 11.53 2,540 43.85 0.0107
2024-05-15 2024-03-31 13F CORCEPT THERAPEUTICS COM 218352102 70,090 70,090 1,766 0.0085
2019-08-20 2019-06-30 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 0 -159 -100.00 0 -100.00
2019-05-15 2019-03-31 13F CORCEPT THERAPEUTICS COM 218352102 159 -19 -10.67 2 0.00 0.0001
2019-05-21 2018-12-31 13F/A-1 CORCEPT THERAPEUTICS COM 218352102 178 178 2 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.